Allogene Therapeutics (ALLO) Short Interest Ratio & Short Volume $1.56 -0.05 (-2.80%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Allogene Therapeutics Short Interest DataAllogene Therapeutics (ALLO) has a short interest of 34.76 million shares, representing 24.91% of the float (the number of shares available for trading by the public). This marks a -8.55% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.5, indicating that it would take 6.5 days of the average trading volume of 4.89 million shares to cover all short positions.Current Short Interest34,760,000 sharesPrevious Short Interest38,010,000 sharesChange Vs. Previous Month-8.55%Dollar Volume Sold Short$50.75 millionShort Interest Ratio6.5 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares217,265,000 sharesFloat Size139,530,000 sharesShort Percent of Float24.91%Today's Trading Volume1,160,584 sharesAverage Trading Volume4,885,933 sharesToday's Volume Vs. Average24% Short Selling Allogene Therapeutics? Sign up to receive the latest short interest report for Allogene Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALLO Short Interest Over TimeALLO Days to Cover Over TimeALLO Percentage of Float Shorted Over Time Allogene Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202534,760,000 shares $50.75 million -8.6%24.9%6.5 $1.46 3/15/202538,010,000 shares $73.74 million -2.8%27.2%7.1 $1.94 2/28/202539,100,000 shares $76.25 million +16.2%29.1%7.6 $1.95 2/15/202533,660,000 shares $68.67 million +5.0%25.0%6.7 $2.04 1/31/202532,050,000 shares $57.69 million -0.9%22.8%11.7 $1.80 1/15/202532,350,000 shares $60.49 million +4.7%N/A12 $1.87 12/31/202430,910,000 shares $65.84 million -4.5%N/A12.4 $2.13 12/15/202432,370,000 shares $61.18 million +3.9%N/A14.1 $1.89 11/30/202431,170,000 shares $77.30 million -11.1%N/A13.8 $2.48 11/15/202435,050,000 shares $79.56 million -5.4%N/A16.2 $2.27 Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/31/202437,040,000 shares $94.64 million -5.8%26.7%18.7 $2.56 10/15/202439,320,000 shares $106.56 million +2.1%28.5%21.7 $2.71 9/30/202438,510,000 shares $107.83 million -1.7%28.2%18.3 $2.80 9/15/202439,190,000 shares $116.00 million +0.6%28.7%17 $2.96 8/31/202438,940,000 shares $102.41 million -0.7%28.5%15.8 $2.63 8/15/202439,230,000 shares $90.23 million +3.9%28.7%14.5 $2.30 7/31/202437,750,000 shares $110.99 million -12.7%27.6%12.9 $2.94 7/15/202443,230,000 shares $128.83 million +4.5%31.6%14.7 $2.98 6/30/202441,380,000 shares $96.42 million -4.4%30.3%15.3 $2.33 6/15/202443,280,000 shares $101.71 million +6.7%31.7%17.1 $2.35 5/31/202440,570,000 shares $101.43 million +11.4%33.5%16.2 $2.50 5/15/202436,430,000 shares $108.56 million +7.6%30.1%15.7 $2.98 4/30/202433,870,000 shares $93.48 million +8.0%32.0%15.5 $2.76 4/15/202431,360,000 shares $111.33 million +2.4%30.0%13.9 $3.55 3/31/202430,620,000 shares $136.87 million +10.3%29.3%11.7 $4.47 3/15/202427,750,000 shares $129.32 million +11.0%26.6%10 $4.66 2/29/202425,010,000 shares $122.80 million +6.7%24.1%8.3 $4.91 2/15/202423,450,000 shares $116.31 million +1.6%22.6%7.7 $4.96 1/31/202423,090,000 shares $81.28 million -23.6%22.2%7.4 $3.52 1/15/202430,210,000 shares $97.28 million -3.5%28.5%10.3 $3.22 12/31/202331,320,000 shares $100.54 million -6.7%29.6%11.9 $3.21 12/15/202333,550,000 shares $90.92 million +5.3%31.7%14.3 $2.71 11/30/202331,860,000 shares $74.87 million -1.5%30.1%16.8 $2.35 11/15/202332,340,000 shares $87.96 million -5.0%30.6%18.9 $2.72 10/31/202334,030,000 shares $95.96 million +10.7%32.2%22 $2.82 10/15/202330,730,000 shares $98.03 million -10.0%29.2%18 $3.19 9/30/202334,130,000 shares $108.19 million +2.1%32.2%19 $3.17 9/15/202333,420,000 shares $130.00 million +4.1%31.5%16.2 $3.89 8/31/202332,110,000 shares $124.91 million -2.0%30.3%12.4 $3.89 8/15/202332,770,000 shares $133.70 million -13.6%30.9%12.5 $4.08Genius investor: A “wealth window” will close June 25 (Ad)Thanks to President Trump’s genius Executive Order 14179… I believe there’s a new opportunity that will be 10X BIGGER than crypto. A $10,000 investment…Could grow to $1 MILLION or more. If you missed out on a bitcoin fortune, this could be your second chance. A brief “wealth window” is 7/31/202337,910,000 shares $188.03 million -8.1%39.4%14.3 $4.96 7/15/202341,260,000 shares $204.65 million +8.1%53.9%15.3 $4.96 6/30/202338,180,000 shares $189.75 million +1.7%49.9%14.1 $4.97 6/15/202337,560,000 shares $186.67 million -6.2%49.1%15.1 $4.97 5/31/202340,030,000 shares $210.16 million -1.4%52.1%20.4 $5.25 5/15/202340,590,000 shares $273.58 million -0.2%52.8%19.6 $6.74 4/30/202340,650,000 shares $220.73 million -1.4%53.3%20.3 $5.43 4/15/202341,220,000 shares $205.69 million +0.5%54.5%22.2 $4.99 3/31/202341,010,000 shares $202.59 million +3.0%54.3%22.5 $4.94 3/15/202339,800,000 shares $225.27 million +8.0%49.6%20.9 $5.66 2/28/202336,860,000 shares $234.06 million +4.9%46.0%19.4 $6.35 2/15/202335,140,000 shares $254.06 million +2.1%44.0%18.4 $7.23 1/31/202334,410,000 shares $265.65 million +0.7%43.1%18 $7.72 1/15/202334,160,000 shares $241.17 million +2.2%42.7%18.1 $7.06 12/30/202233,430,000 shares $210.27 million +9.5%41.8%18 $6.29 12/15/202230,530,000 shares $216.15 million +0.2%38.2%16 $7.08 11/30/202230,470,000 shares $300.43 million -3.2%38.1%16.5 $9.86 11/15/202231,460,000 shares $311.45 million +1.6%39.3%18.2 $9.90 10/31/202230,960,000 shares $318.89 million +3.0%39.3%18.3 $10.30 10/15/202230,050,000 shares $305.91 million +8.9%38.3%18 $10.18 9/30/202227,590,000 shares $297.97 million +24.2%35.2%16 $10.80 9/15/202222,220,000 shares $311.08 million +0.9%28.3%12.8 $14.00 8/31/202222,020,000 shares $301.89 million -2.4%28.1%12 $13.71 8/15/202222,570,000 shares $390.01 million +0.8%28.8%11.6 $17.28 7/31/202222,400,000 shares $290.75 million -0.1%28.6%10.9 $12.98 7/15/202222,430,000 shares $287.33 million -0.3%28.6%10.2 $12.81 6/30/202222,490,000 shares $256.39 million +2.0%28.5%10.5 $11.40 6/15/202222,060,000 shares $212.22 million +9.5%28.0%10.8 $9.62 5/31/202220,150,000 shares $159.79 million +13.9%25.7%10.8 $7.93 5/15/202217,690,000 shares $127.90 million -0.4%22.5%9.6 $7.23 4/30/202217,760,000 shares $148.30 million -1.7%24.3%10.4 $8.35 4/15/202218,060,000 shares $149.00 million +18.6%24.8%11.4 $8.25 3/31/202215,230,000 shares $138.75 million +4.8%16.1%8.9 $9.11 3/15/202214,540,000 shares $113.41 million +18.7%19.8%8.6 $7.80 2/28/202212,250,000 shares $112.09 million +16.9%16.7%7.5 $9.15 2/15/202210,480,000 shares $106.79 million +10.0%14.3%6.8 $10.19 1/31/20229,530,000 shares $109.12 million +5.1%14.3%6.6 $11.45 1/15/20229,070,000 shares $120.45 million +19.7%13.6%6.2 $13.28 12/31/20217,580,000 shares $113.09 million +34.9%11.4%4.1 $14.92 12/15/20215,620,000 shares $86.38 million +4.7%8.4%2.7 $15.37 11/30/20215,370,000 shares $99.29 million -5.3%8.1%2.9 $18.49 11/15/20215,670,000 shares $106.99 million +19.6%8.5%3.1 $18.87 10/29/20214,740,000 shares $81.72 million +0.2%7.1%2.6 $17.24 10/15/20214,730,000 shares $77.95 million -40.7%7.1%2.8 $16.48 9/30/20217,980,000 shares $205.09 million +1.7%12.0%6.7 $25.70 9/15/20217,850,000 shares $196.25 million -6.0%11.8%9.5 $25.00 8/31/20218,350,000 shares $199.15 million -0.4%11.7%9.4 $23.85 8/13/20218,380,000 shares $179.67 million -9.6%11.7%7.5 $21.44 7/30/20219,270,000 shares $203.48 million -2.2%13.0%7.1 $21.95 7/15/20219,480,000 shares $211.88 million +0.2%13.3%7.1 $22.35Genius investor: A “wealth window” will close June 25 (Ad)Thanks to President Trump’s genius Executive Order 14179… I believe there’s a new opportunity that will be 10X BIGGER than crypto. A $10,000 investment…Could grow to $1 MILLION or more. If you missed out on a bitcoin fortune, this could be your second chance. A brief “wealth window” is 6/30/20219,460,000 shares $246.72 million +15.5%13.3%7 $26.08 6/15/20218,190,000 shares $205.00 million +3.0%11.5%7 $25.03 5/28/20217,950,000 shares $204.32 million -3.4%11.3%6.8 $25.70 5/14/20218,230,000 shares $221.72 million +13.5%11.6%7.8 $26.94 4/30/20217,250,000 shares $231.86 million -12.7%10.2%8.5 $31.98 4/15/20218,300,000 shares $266.85 million -3.8%11.9%10.1 $32.15 3/31/20218,630,000 shares $288.50 million -16.1%12.4%10 $33.43 3/15/202110,290,000 shares $395.96 million -10.9%14.6%11.1 $38.48 2/26/202111,550,000 shares $378.72 million +4.2%16.5%12.4 $32.79 2/12/202111,080,000 shares $381.15 million -4.0%15.8%12.6 $34.40 1/29/202111,540,000 shares $398.25 million -15.9%16.8%12.8 $34.51 1/15/202113,720,000 shares $426.28 million +5.2%20.1%14.8 $31.07 12/31/202013,040,000 shares $347.39 million +15.7%19.1%15.4 $26.64 12/15/202011,270,000 shares $315.56 million +5.8%16.5%13.8 $28.00 11/30/202010,650,000 shares $335.69 million +0.7%15.7%14.1 $31.52 11/15/202010,580,000 shares $339.30 million +5.1%15.6%15.4 $32.07 10/30/202010,070,000 shares $358.19 million -0.5%14.9%15.5 $35.57 10/15/202010,120,000 shares $436.88 million -2.3%15.0%17.2 $43.17 9/30/202010,360,000 shares $390.68 million +1.5%15.4%17.7 $37.71 9/15/202010,210,000 shares $363.58 million -5.0%15.1%16.3 $35.61 8/31/202010,750,000 shares $383.24 million +0.6%15.9%16.6 $35.65 8/14/202010,690,000 shares $394.78 million -2.8%15.9%11.9 $36.93 7/31/202011,000,000 shares $403.37 million -8.8%16.7%9.6 $36.67 7/15/202012,060,000 shares $501.58 million -10.1%18.4%10.1 $41.59 6/30/202013,420,000 shares $561.76 million +16.8%23.3%10.9 $41.86 6/15/202011,490,000 shares $482.69 million -13.3%20.2%9.5 $42.01 5/29/202013,250,000 shares $638.12 million -1.6%23.6%10.9 $48.16 5/15/202013,460,000 shares $604.49 million +2.2%26.5%12.9 $44.91 4/30/202013,170,000 shares $380.61 million -6.7%26.0%17.4 $28.90 ALLO Short Interest - Frequently Asked Questions What is Allogene Therapeutics' current short interest? Short interest is the volume of Allogene Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 34,760,000 shares of ALLO short. 24.91% of Allogene Therapeutics' shares are currently sold short. Learn More on Allogene Therapeutics' current short interest. What is a good short interest ratio for Allogene Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALLO shares currently have a short interest ratio of 6.0. Learn More on Allogene Therapeutics's short interest ratio. Which institutional investors are shorting Allogene Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Allogene Therapeutics: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Allogene Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 24.91% of Allogene Therapeutics' floating shares are currently sold short. Is Allogene Therapeutics' short interest increasing or decreasing? Allogene Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 34,760,000 shares, a drop of 8.6% from the previous total of 38,010,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Allogene Therapeutics' float size? Allogene Therapeutics currently has issued a total of 217,265,000 shares. Some of Allogene Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Allogene Therapeutics currently has a public float of 139,530,000 shares. How does Allogene Therapeutics' short interest compare to its competitors? 24.91% of Allogene Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Allogene Therapeutics: Ocular Therapeutix, Inc. (8.30%), Evotec SE (0.24%), Amphastar Pharmaceuticals, Inc. (9.72%), Adaptive Biotechnologies Co. (7.31%), Iovance Biotherapeutics, Inc. (28.32%), Ardelyx, Inc. (13.75%), Structure Therapeutics Inc. (12.69%), Aurinia Pharmaceuticals Inc. (9.41%), Syndax Pharmaceuticals, Inc. (23.65%), Wave Life Sciences Ltd. (9.19%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Allogene Therapeutics stock? Short selling ALLO is an investing strategy that aims to generate trading profit from Allogene Therapeutics as its price is falling. ALLO shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Allogene Therapeutics? A short squeeze for Allogene Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALLO, which in turn drives the price of the stock up even further. How often is Allogene Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALLO, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Ocular Therapeutix Short Squeeze Evotec Short Squeeze Amphastar Pharmaceuticals Short Squeeze Adaptive Biotechnologies Short Squeeze Iovance Biotherapeutics Short Squeeze Ardelyx Short Squeeze Structure Therapeutics Short Squeeze Aurinia Pharmaceuticals Short Squeeze Syndax Pharmaceuticals Short Squeeze Wave Life Sciences Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALLO) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLO Stock Free ALLO Stock Alerts